Clinical trials: Metabolism and Excretion
Hypercholesterolemia, Coronary Heart Disease
Comparison of Low and High Phytosterol Diets With Respect to Cholesterol Metabolism
The objective of this study is to compare cholesterol absorption and metabolism after feeding diets naturally low or high in phytosterols. All meals will be prepared in a metabolic kitchen and analyzed for phytosterols.
- Trial name
- Phyteaux-II (NCT00860509)
- Testing
- Low Phytosterol and High Phytosterol Diets
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Healthy Volunteers
A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants
The primary purpose of this study is to determine the metabolism and excretion of [14C]E2086 in healthy male participants.
- Trial name
- NCT07308236
- Testing
- E2086
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Healthy
A Study of [14C]-LY3537982 in Healthy Participants
The main purpose of this study is to conduct blood tests to measure how much LY3537982 is in the bloodstream and how the body handles and eliminates LY3537982 in healthy participants.
- Trial name
- NCT05901311
- Testing
- LY3537982, [¹⁴C]-LY3537982
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
Absorption, Metabolism, and Excretion Study of [14C]-TNP-2092
This is an open-label, single dose, Phase 1 study conducted at a single study center in the United States (USA). This study will evaluate the absorption, metabolism and elimination (AME), mass balance, safety and tolerability of…
- Trial name
- NCT05074134
- Testing
- [14C]-TNP-2092
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- TenNor Therapeutics Limited
Healthy
Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects
This phase 1 study is to evaluate the pharmacokinetics (PK), metabolism, routes and extent of elimination of a single oral dose of 400 mg [14C]LX4211 to healthy male subjects
- Trial name
- AME (NCT01818232)
- Testing
- [14C]-LX4211
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Lexicon Pharmaceuticals
Healthy Adult Male
A Phase I, Open-Label Trial to Assess the Absorption, Metabolism, and Excretion of (14C)-OPC-61815 in Healthy Male Japanese Subjects
To determine the mass balance of totalradioactivity following a single IV infusionof (14C)-OPC-61815. To determine routes and rates of elimination of total radioactivity following a single IV infusion of (14C)-OPC-61815 To assess…
- Trial name
- NCT04182958
- Testing
- (14C)-OPC-61815
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Healthy Volunteer
Phase 1 Study to Evaluate ASN002 Absorption, Metabolism, and Excretion of [14C] Following a Single Oral Dose in Healthy Male Subjects
Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C] ASN002 Following a Single Oral Dose in Healthy Male Subjects
- Trial name
- NCT03641573
- Testing
- [14C] ASN002
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Asana BioSciences
Chronic Underhydration, Thirst; Due to Deprivation of Water
Effects of Habitual Water Intake on Thirst in Healthy Young Adults Explained by Osmoadaptive Metabolism, Brain and Kidney Function (Adapt-Thirst)
Social relevance: For 30 years, people have been confused about how much plain water to drink. Over 30 years, health professionals have criticized media advice to drink 8 glasses of water per day, citing lack of evidence (Valtin…
- Conditions
- Chronic Underhydration, Thirst; Due to Deprivation of Water, Aestivation Metabolism, Warburg Effect
- Trial name
- Adapt-Thirst (NCT07464002)
- Testing
- Drinking water to dilute urine
- Volunteers
- 120 people
- Sponsor
- Jodi Stookey
Schizophrenia
A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral Dose
The purposes of this study are to investigate the metabolic pathways of paliperidone and excretion of paliperidone and its metabolites in healthy adult male volunteers, both CYP2D6 poor and extensive metabolizers, after…
- Trial name
- NCT00796029
- Testing
- 14C-paliperidone
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy
A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6
This is a single-center, non-randomized, open-label Phase 1 study to characterize the absorption, metabolism, excretion, mass balance, pharmacokinetics (PK), safety and tolerability of HU6 following administration of a single…
- Trial name
- NCT06325930
- Testing
- [14C]-HU6
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Rivus Pharmaceuticals, Inc.
Osteoporosis
A Study To Investigate The Metabolism And Excretion Of 14C SB-751689 Given To Healthy Males And Postmenopausal Women
This study will examine the biological fate of radioactive SB-751689 administered to healthy males and healthy postmenopausal women. Subjects will receive a single oral dose of radioactive SB-751689.
- Trial name
- NCT00499928
- Testing
- SB-751689
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Osteoporosis
A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women
SB-751689 may alter calcium and phosphate handling at the kidney level. This study will examine what happens to calcium and phosphate, and other electrolytes, at the kidney after treatment with SB-751689 for 1 month.
- Trial name
- NCT00532077
- Testing
- rhPTH(1-34), SB-751689 100 mg, SB-751689 400 mg
- Where
- 5 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study of (14C)-JNJ-73841937 (Lazertinib) in Healthy Male Participants
The purpose of this study is to characterize the absorption, metabolic pathways of lazertinib, and the excretion of the parent lazertinib and its metabolites, after a single oral dose of 14C-lazertinib in healthy adult male…
- Trial name
- NCT04410081
- Testing
- 14C-lazertinib
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study to Understand How a Study Medicine Called PF-07328948 is Absorbed and Processed in the Body of Healthy Male Adults
The purpose of this study is to learn how a certain amount of [14C] PF-07320948 is taken up into the bloodstream and removed from the body.
- Trial name
- NCT07508228
- Testing
- Oral [14C]PF-07328948, Oral Unlabeled PF-07328948, IV [14C]PF-07328948
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pfizer
Prediabetes
Glycemic Response to Two Doses of Low Sugar Apple Juice
Single center, double-blind, randomized controlled cross-over trial with four treatments and four time points. The study has three primary objectives.
- Trial name
- HB-RCT2-2015 (NCT04747639)
- Testing
- 500 ml glucose-depleted apple juice, 500 ml conventional apple juice, 250 ml glucose-depleted apple juice
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- Clinical Research Center Kiel GmbH
Healthy
Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine
The purpose of the study is to learn more about how esreboxetine is handled by the body i.e. the absorption, metabolism and excretion of esreboxetine.
- Trial name
- ADME (NCT00800956)
- Testing
- [14C]-esreboxetine
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hyperphagia, Prader-Willi Syndrome
The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial
The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS) when used in a long term setting. It will also teach us about the safety of ARD-101.
- Conditions
- Hyperphagia, Prader-Willi Syndrome, Hyperphagia in Prader-Willi Syndrome
- Trial name
- NCT07197034
- Testing
- ARD-101
- Where
- 30 sites in United States, Australia and 3 more
- Volunteers
- 19 people
- Sponsor
- Aardvark Therapeutics, Inc.
Healthy Subjects
An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of 14C-Perampanel in Healthy Male Subjects
This is an open-label, single-dose study in healthy male subjects. The study will have 2 phases: Pretreatment and Treatment. The Pretreatment Phase will last up to 21 days and will consist of a Screening Period and a Baseline…
- Trial name
- NCT02116907
- Testing
- E2007
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Healthy
Open Label, Healthy Volunteers, ADME Study With Single Oral Administration of [14C] AZD5069
This is a phase I, open label, healthy volunteers, ADME study with single oral administration of [14C] AZD5069.
- Trial name
- NCT01332903
- Testing
- [14C] AZD5069
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects
The purpose of the study is to characterize the metabolism and excretion (ADME) of a single oral dose of [14C]varespladib methyl.
- Trial name
- NCT01359605
- Testing
- varespladib methyl
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Anthera Pharmaceuticals